Sera Prognostics, Inc. (SERA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reflects mixed sentiments. While there are positive aspects like disciplined expense management and promising partner programs, the company faces significant commercialization challenges and financial losses. The Q&A section indicates some optimism with stakeholder engagement and strategic partnerships, yet uncertainties in payer coverage and market access persist. The financial metrics reveal modest revenue and ongoing losses, with a stable cash position but slow growth. These factors balance out, leading to a neutral stock price prediction in the short term.
Key Financial Performance
Fourth Quarter Revenue $10,000, down from $24,000 in Q4 2024. Revenue remains modest and fluctuates due to the early commercial stage.
Fourth Quarter Operating Expenses $9 million, down from $9.4 million in Q4 2024. Reflects disciplined expense management.
Fourth Quarter Research and Development Expenses $3.2 million, slightly up from $3.1 million in Q4 2024. Expected to decrease as resources shift to commercialization.
Fourth Quarter Selling, General and Administrative Expenses $5.7 million, down from $6.3 million in Q4 2024. Reflects targeted commercial initiatives and strategic headcount.
Fourth Quarter Net Loss $7.9 million, improved from $8.6 million in Q4 2024. Demonstrates disciplined capital deployment.
Full Year Revenue $81,000, up slightly from $77,000 in 2024. Reflects early commercial stage.
Full Year Total Expenses $36.6 million, nearly flat compared to $36.7 million in 2024. Reflects capital reallocation from R&D to commercial activities.
Full Year Research and Development Expenses $13.2 million, down from $14.7 million in 2024. Driven by lower clinical study costs following PRIME completion.
Full Year Selling, General and Administrative Expenses $23.3 million, up from $21.9 million in 2024. Due to targeted commercial readiness investments.
Full Year Net Loss $31.9 million, improved from $32.9 million in 2024. Reflects disciplined capital deployment.
Cash Position at Year-End $95.8 million in cash, cash equivalents, and available-for-sale securities. Expected to fund operations through 2028.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
PRIME study publication: The PRIME study was finalized and published in December 2025, with a full manuscript released in January 2026. It showed significant reductions in preterm births: 56% fewer babies born before 32 weeks and 32% fewer before 35 weeks of gestation.
PreTRM Test: The PreTRM Test is designed to identify women at higher risk of preterm birth early in the second trimester. It uses a biomarker-based approach and has been integrated into a standardized care pathway.
U.S. Medicaid and commercial payer engagement: Engaged with payers across 13 states in 2025, exceeding initial goals. Plans to expand to 15-17 states by the end of 2026, covering 58%-60% of U.S. births. Partner Programs are being used to generate outcomes data and support reimbursement expansion.
European market expansion: Progressing towards CE marking approval for the PreTRM Global Test. Submission of the European dossier is expected in the coming months. European commentary aligns the PRIME study approach with healthcare systems in the region.
Operational efficiencies: Refined ordering experience, expanded field education, and enhanced onboarding to integrate PreTRM into clinical workflows. Focused on repeat ordering and scaling within early adopter providers.
Financial discipline: Operating expenses for 2025 were $36.6 million, consistent with 2024. Cash reserves of $95.8 million are expected to fund operations through 2028.
Capital allocation strategy: Prioritizing investments in market access, commercial scale-up, and evidence generation while maintaining financial discipline. Renewed ATM facility for financial flexibility.
Leadership enhancements: Added key leadership roles, including a new Head of Sales and Strategic Accounts, to strengthen commercial execution and adoption of PreTRM.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Fluctuations: Revenue remains modest and can fluctuate from period to period in this early commercial stage, with Q4 2025 revenue at $10,000 compared to $24,000 in Q4 2024. This indicates challenges in achieving consistent revenue growth.
Operating Expenses: Operating expenses for Q4 2025 were $9 million, reflecting high costs relative to revenue, which could strain financial resources if revenue growth does not accelerate.
Net Loss: The company reported a net loss of $7.9 million for Q4 2025 and $31.9 million for the full year, highlighting ongoing financial challenges and the need for effective cost management.
Commercialization Challenges: The company is in the early stages of commercialization, with limited revenue and reliance on Partner Programs to drive adoption and payer coverage, which may take time to yield results.
Regulatory and Market Access Risks: Efforts to secure CE marking approval in Europe and payer coverage in the U.S. are ongoing, with potential delays or challenges in achieving these milestones.
Dependence on Evidence Generation: The company relies heavily on generating real-world evidence and outcomes data to support payer coverage and clinical adoption, which could delay broader market penetration if results are not timely or favorable.
Cash Burn and Runway: While the company has $95.8 million in cash and expects this to fund operations through 2028, high expenses and slow revenue growth could pressure financial sustainability.
Competitive and Market Dynamics: The company faces competitive pressures and the need to educate providers and payers about its PreTRM test, which could slow adoption and market penetration.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Commercial Expansion in 2026: The company plans to expand its Partner Programs to 15-17 states by the end of 2026, representing 58%-60% of U.S. births. They aim to run 5-7 active Partner Programs by year-end, focusing on Medicaid and commercial payers to generate outcomes data supporting clinical adoption and reimbursement.
European Market Entry: Sera Prognostics is working towards CE marking approval for the PreTRM Global Test and plans to submit its European dossier in the coming months. The company is building the foundation for market entry following regulatory clearance.
Revenue Growth Expectations: Revenue growth is expected to build gradually as Partner Programs mature and real-world evidence results are generated and disseminated.
Real-World Evidence Generation: The company plans to generate real-world evidence across diverse populations, care settings, and payer environments to support guideline inclusion, payer policy updates, and adoption.
Capital Allocation and Financial Strategy: Sera Prognostics has $95.8 million in cash and expects this to fund operations through 2028. The company will prioritize investments in market access, commercial scale-up, and evidence generation while maintaining financial discipline.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you expand on converting payer discussions and Partner Programs using outcomes and economic data?
A:Lee Anderson explained that the Partner Program approach involves entities evaluating clinical outcomes and economic benefits, such as a 20% reduction in NICU admissions. Tiffany Inglis added that NICU utilization is a major cost driver, and the program helps address this issue. They are conducting sub-analysis and evidence generation post-PRIME to further support these claims.
Q:What feedback was received at the SMFM conference, and how have conversations evolved since then?
A:Tiffany Inglis noted significant engagement with providers and SMFM leadership, focusing on making the test more accessible to women. Evguenia Lindgardt added that the study has improved engagement across various stakeholders, including providers, payers, and legislators, and they are seeing positive signals about evolving standards of care.
Q:How is the company planning to balance investments in U.S. states versus the global EU launch, and will SG&A spend accelerate this year?
A:Austin Aerts stated that cash OpEx is budgeted to remain similar to last year, with a shift in spending from clinical and R&D activities to commercial activities, including significant investment in the EU. They will reallocate capital as commercial opportunities develop.
Q:Can you elaborate on the profile of the second active partnership program and how it differs from the first?
A:Lee Anderson mentioned that the second partner is an employer collaborative operating in multiple states, starting with one state and potentially expanding. Partnerships vary, including large health systems, IDNs, provider payers, and group practices. Evguenia Lindgardt added that they are partnering with diverse entities, such as legislative bodies, midwife associations, and telehealth providers.
Q:Review of Unclear Management Responses
A:No questions were identified where management avoided giving a direct answer or lacked clarity in their responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Anderson Chief
Journal
MFM
Maternal Fetal
Medicaid agency
Medicine
OB
PRIME outcome
Partner Program
Tiffany
access infrastructure
affordability
awareness effort
burden
campaign provider
care pathway
center
champion
cohort
collaboration
coverage pathway
department
discussion state
education
engagement coverage
evidence result
form
goal
health outcome
health system
identification
partner program
payer discussion
payer review
program end
region
repeat adopter
symptom
track
SERA Transcript
Sera Prognostics, Inc. (SERA) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call reflects mixed sentiments. While there are positive aspects like disciplined expense management and promising partner programs, the company faces significant commercialization challenges and financial losses. The Q&A section indicates some optimism with stakeholder engagement and strategic partnerships, yet uncertainties in payer coverage and market access persist. The financial metrics reveal modest revenue and ongoing losses, with a stable cash position but slow growth. These factors balance out, leading to a neutral stock price prediction in the short term.
Sera Prognostics, Inc. (SERA) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call presents a mixed picture. Financial performance is weak, with a significant revenue decline, though cash reserves remain strong. The company is making strategic moves, like Medicaid pilots and European expansion, but faces regulatory and payer engagement risks. The Q&A reveals confidence in Medicaid progress and the upcoming PRIME publication, but management's reluctance to disclose economic specifics and guideline timelines adds uncertainty. Overall, the sentiment is neutral, as positive strategic developments are offset by financial challenges and uncertainties.
Sera Prognostics, Inc. (SERA) Q2 2025 Earnings Call Transcript
Unknown8-7
The earnings call highlights several concerns: a decline in net revenue, high operating expenses, and challenges in regulatory and reimbursement approvals. The Q&A reveals delays in guideline inclusion and vague responses on sales force expansion. Despite plans for European market entry, the financial strain and uncertainties overshadow potential growth. The stock price is likely to experience a negative reaction in the short term due to these factors.
Sera Prognostics Inc (SERA) Q4 2024 Earnings Call Transcript
Unknown3-19
The earnings call reflects a mixed outlook with key negative elements. Financial performance shows a significant revenue decline and increased losses, overshadowing optimistic guidance. The public offering dilutes shareholder value, and competitive, regulatory, and market adoption risks are evident. Despite promising growth initiatives, the lack of clear revenue guidance and increased operational expenses raise concerns. The Q&A section did not alleviate these issues, suggesting a negative sentiment overall. Without market cap data, the prediction remains cautious, but the negative factors dominate, suggesting a likely stock price decline of -2% to -8%.
SERA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
